Dr. Eisner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
826 Main St
Ste 100
Phoenixville, PA 19460Phone+1 610-933-8484Fax+1 610-917-0320
Education & Training
Temple University HospitalFellowship, Allergy and Immunology, 1966 - 1967- Temple University HospitalResidency, Internal Medicine, 1964 - 1966
- Temple University HospitalInternship, Internal Medicine, 1963 - 1964
Albert Einstein College of MedicineClass of 1963
Certifications & Licensure
PA State Medical License 1964 - 2026
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2014
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2014
Publications & Presentations
PubMed
- 43 citationsHighly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.Stephen W. Rafferty, Joel R. Eisner, William R. Moore, Robert J. Schotzinger, William J. Hoekstra
Bioorganic & Medicinal Chemistry Letters. 2014-06-01 - 34 citationsPrenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.Cristin M. Bruns, Scott T Baum, Ricki J. Colman, Daniel A. Dumesic, Joel R. Eisner
International Journal of Obesity. 2007-05-01 - 68 citationsInsulin Resistance and Impaired Insulin Secretion in Prenatally Androgenized Male Rhesus MonkeysCristin M. Bruns, Scott T Baum, Ricki J. Colman, Joel R. Eisner, Joseph W. Kemnitz
The Journal of Clinical Endocrinology and Metabolism. 2004-12-01
Press Mentions
Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation StatusJuly 22nd, 2021
Other Languages
- Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
